Day: April 25, 2022

Accelerates MDLZ growth in core snacking categories in high-priority Mexico market Acquiring iconic chocolate and candy brands including Ricolino, Vero, La Corona and Coronado – strong strategic complements to MDLZ portfolio Expands route-to-market capabilities with more than 2,100 DSD routes, reaching 440,00 traditional trade outletsCHICAGO, April 25, 2022 (GLOBE NEWSWIRE) — Mondelēz International (Nasdaq: MDLZ) today announced it has entered into an agreement with Grupo Bimbo to acquire its confectionery business, Ricolino, for approximately $1.3 billion USD. Ricolino is a growing business with a leading confectionery position in Mexico. The acquisition will transform Mondelēz International’s business in the high-priority Mexico market to accelerate growth and scale in core snacking categories. With approximately $500 million...

PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference taking place from April 27-28, 2022. Management’s conversation during the event will cover the progress on clinical programs within Cognition’s neurodegenerative and ophthalmological drug pipeline. A webcasts of this fireside chat will be available at https://www.webcaster4.com/Webcast/Page/2875/45362 and archived on the “Events and Presentations” section of the Cognition Therapeutics website. Details of the event are as follows: Presentation...

Encouraging results including a 11.5m intersected zone with brecciated and faulted basement rock that displayed strong hydrothermal clay alterationHearty Bay 2022 Work Program Hearty Bay 2022 Work ProgramVANCOUVER, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) — Traction Uranium Corp. (the “Company” or “Traction”) (CSE: TRAC) (OTC: TRT) (FRA: Z1K), a mineral exploration issuer focusing on the development of discovery prospects in Canada, including its two flagship uranium projects in the world-renowned Athabasca Region, is pleased to report the completion of the diamond drilling program at Hearty Bay, located in the Saskatchewan Athabasca Region. Fourteen (14) diamond drill holes have been completed for 1,304 metres of diamond drilling in the program as well as 77-line kilometers of ground electromagnetic (EM) geophysics. Highlights...

HOUSTON, April 25, 2022 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY), the leading global foodservice distribution company, congratulates Tom Peck, Sysco’s executive vice president and chief information and digital officer on being recognized as the 2022 Houston CIO of the Year ORBIE Awards winner in the Super Global category. The prestigious CIO of the Year ORBIE Award is a leading technology executive recognition program honoring the CIOs who are driving innovation and transforming Houston’s leading organizations. “I am very proud to congratulate Tom on this achievement,” said Kevin Hourican, Sysco’s president and chief executive officer. “He leads the development of many critical customer-facing technology solutions that underpin Sysco’s Recipe for Growth business strategy. I’m especially proud of how Tom led the Technology...

Conference Call and Webcast Scheduled for Thursday, May 5th at 5:00 pm ET RADNOR, Pa., April 25, 2022 (GLOBE NEWSWIRE) — Safeguard Scientifics, Inc. (NYSE:SFE) will release its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022. CONFERENCE CALL AND WEBCAST DETAILS Please call 10-15 minutes prior to the call to register. Date:   Thursday, May 5, 2022 Time:   5:00 pm ET Live Number:   888-482-7458   Webcast link: https://www.webcast-eqs.com/safeguard05052022_en/en Speakers:   Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon Format:   Discussion of the first quarter of 2022 financial results followed by Q&A The replay will also be available at the webcast link above. For more information please contact IR@safeguard.com.  About...

SALT LAKE CITY, April 25, 2022 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor and consumer enthusiast markets, will hold a conference call on Monday, May 9, 2022, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Date: Monday, May 9, 2022Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time) Toll-free dial-in number: 1-877-511-3707International dial-in number: 1-786-815-8672Conference ID: 3778768 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty...

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)–  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–  Further substantiates potential of AMT-101 and Company’s oral biologics platform–  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced positive top-line Phase 2 results from the FILLMORE monotherapy trial for AMT-101...

MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules. The cytotoxic effects of the subject mRNA molecules were tested on different cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). In contrast to cancer...